Innovative Clinical Research Inc is categorized under Medical Research in Carlsbad, CA and active since 2010.
Innovative Clinical Research Inc was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Hoang-Thu Tar-Noy at the company’s single location by writing to 2720 Loker Avenue West # Q, Carlsbad, California CA 92010 or by phoning (760) 444-9040. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Innovative Clinical Research Inc |
| Contact Person: | Hoang-Thu Tar-Noy |
| Address: | 2720 Loker Avenue West # Q, Carlsbad, California 92010 |
| Phone Number: | (760) 444-9040 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Innovative Clinical Research Inc was started in 2010 to provide professional Medical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Hoang-Thu Tar-Noy for inquiries that concern Innovative Clinical Research Inc by calling the company number (760) 444-9040, as your correspondence is most welcome. Additionally, the physical location of the single location of Innovative Clinical Research Inc can be found at the coordinates as well as the street address 2720 Loker Avenue West # Q in Carlsbad, California 92010.
For its online presence, you may visit Innovative Clinical Research Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.